[{"Assets_0_Q3_USD":891464000.0,"CommonStockSharesOutstanding_0_Q3_shares":52708767.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-283270000.0,"NetIncomeLoss_1_Q3_USD":-89864000.0,"NetIncomeLoss_3_Q3_USD":-268750000.0,"StockholdersEquity_0_Q3_USD":233666000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q3_USD":22757000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_3_Q3_USD":65037000.0,"Ticker":"CLVS","CIK":"1466301","name":"CLOVIS ONCOLOGY, INC.","OfficialName":"Clovis Oncology Inc. Common Stock","form":"10-Q","period":"20180930","fy":"2018.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"317205570.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20181101"}]